Fig. 4From: DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthmaTreatment groupings across the predecessor (NAVIGATOR or SOURCE) studies and the DESTINATION LTE study. LTE long-term extensionBack to article page